Prosecution Insights
Last updated: May 29, 2026
Application No. 17/618,333

ANTIBIOTIC COMPOUNDS

Non-Final OA §102
Filed
Dec 10, 2021
Priority
Jun 12, 2019 — provisional 62/860,475 +1 more
Examiner
HABTE, KAHSAY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Emory University
OA Round
5 (Non-Final)
85%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1358 granted / 1599 resolved
+24.9% vs TC avg
Moderate +7% lift
Without
With
+7.3%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 8m
Avg Prosecution
56 currently pending
Career history
1640
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
3.5%
-36.5% vs TC avg
§102
9.1%
-30.9% vs TC avg
§112
63.9%
+23.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1599 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 5-6, 8-18, and 20-21 are pending in this application. Response to Amendment Applicant’s amendment filed 11/19/2025 in response to the previous Office Action (02/03/2025) is acknowledged. Rejection of claims 1-9 under 35 U.S.C. 103 (items 7-9) has been obviated. Election/Restrictions Applicant’s election without traverse of Group I in the reply filed on 10/08/2024 is acknowledged. The examiner attempted to search applicant’s elected invention of Group I, but the search could not go to completion. During a telephone call with Mr. Caleb Bates on 10/30/2024, applicants elect a generic species wherein W = S; L1 = L2 = absent; and X1 – X4 = halo and as a single disclosed species applicants elect a first species in claim 8 to initiate the search. PNG media_image1.png 107 195 media_image1.png Greyscale Previously on 11/04/2024 and 02/03/2025, the examiner searched the elected species and expanded the search focusing on X1-X4 = halo and stopped when a prior art was found. After the response of the previous Office Action dated 05/19/2025, the examiner expanded the search after applicant’s amendment of claim 1 and stopped again when a prior art was found. Note that the search is ongoing. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kawada et al. Bokin Bobai (1988), 16(4), 171-5. Cited reference teaches the following antibacterial compounds that are the same as applicants when applicant’s Formula (I) has the following substituents: X1 = X2 = alkyl; and X2 = X4 = F. PNG media_image2.png 438 1154 media_image2.png Greyscale PNG media_image3.png 428 1111 media_image3.png Greyscale Since said compounds are the same s applicants, a 102(a)(1) rejection is proper. Objection Claims 5-6 and 8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte Ph.D. whose telephone number is (571)272-0667. The examiner can normally be reached on 8:30 - 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY MURRAY can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Kahsay Habte/ Primary Examiner, Art Unit 1624 December 18, 2025
Read full office action

Prosecution Timeline

Show 6 earlier events
Apr 30, 2025
Request for Continued Examination
May 04, 2025
Response after Non-Final Action
May 19, 2025
Non-Final Rejection mailed — §102
Nov 19, 2025
Response Filed
Dec 22, 2025
Final Rejection mailed — §102
May 19, 2026
Request for Continued Examination
May 20, 2026
Response after Non-Final Action
May 26, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637474
FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF
3y 6m to grant Granted May 26, 2026
Patent 12637450
TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS
1y 11m to grant Granted May 26, 2026
Patent 12628827
ISOXAZOLINE COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS
2y 11m to grant Granted May 19, 2026
Patent 12630566
KRAS G12D INHIBITORS
2y 0m to grant Granted May 19, 2026
Patent 12624052
KRAS MODULATORS AND USES THEREOF
2y 3m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
85%
Grant Probability
92%
With Interview (+7.3%)
1y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1599 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month